<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Biweekly schedule of <z:chebi fb="0" ids="31348">capecitabine</z:chebi> combined with irinotecan (XELIRI), consecutively with irinotecan and <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> (XELIRINOX), was evaluated in patients with <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastatic cancer</z:e> from any <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumors</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>PATIENTS AND METHODS: In this two-step phase I trial, seventeen and eleven patients were enrolled in the XELIRI and XELIRINOX stages, respectively </plain></SENT>
<SENT sid="2" pm="."><plain>RESULTS: In XELIRI, a total of 136 chemotherapy cycles were administered with a median number of 8 cycles per patient (2-16) </plain></SENT>
<SENT sid="3" pm="."><plain>Main dose-limiting toxicities (DLT) were grade 3-4 <z:hpo ids='HP_0001875'>neutropenia</z:hpo>, with one toxicity-related <z:hpo ids='HP_0011420'>death</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>Maximum tolerated dose (MTD) for <z:chebi fb="0" ids="31348">capecitabine</z:chebi> combined with 180 mg/m(2) of irinotecan was 3,500 mg/m(2)/day </plain></SENT>
<SENT sid="5" pm="."><plain>In XELIRINOX, <z:chebi fb="0" ids="31348">capecitabine</z:chebi> starting dose was 2,500 mg/m(2)/day </plain></SENT>
<SENT sid="6" pm="."><plain>Fifty-eight chemotherapy cycles were administered with a median of 4 cycles per patient (1-16) </plain></SENT>
<SENT sid="7" pm="."><plain>DLT included 3 grade 4 <z:hpo ids='HP_0001875'>neutropenia</z:hpo>, associated with 1 grade 3 <z:hpo ids='HP_0002014'>diarrhea</z:hpo>, and 1 grade 4 pneumopathy leading to patient <z:hpo ids='HP_0011420'>death</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>MTD for <z:chebi fb="0" ids="31348">capecitabine</z:chebi> with 180 mg/m(2) of irinotecan and 85 mg/m(2) of <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> was 3,000 mg/m(2)/day </plain></SENT>
<SENT sid="9" pm="."><plain>The recommended doses for <z:chebi fb="0" ids="31348">capecitabine</z:chebi> were 3,000 and 2,500 mg/m(2)/day D1-D7 in combination with 180 mg/m(2) of irinotecan in XELIRI, plus 85 mg/m(2) of <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> in XELIRINOX (D1 = D14), respectively </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSION: XELIRI and XELIRINOX regimens are feasible and warrant further investigation in combination with targeted therapy in <z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">metastatic colorectal cancer</z:e> patients </plain></SENT>
</text></document>